Table 1 Descriptive statistics stratified by outcome (mRS 0–2 and 3–6 at discharge) on 241 patients
mRS | 3–6 | 0–2 | Total | p |
|---|---|---|---|---|
(N = 170) | (N = 71) | (N = 241) | ||
Age | ||||
 N | 170 | 71 | 241 | 0.002tt2 |
 Mean ± SD | 57 ± 13 | 51 ± 13 | 55 ± 13 |  |
 Median (Q1, Q3) | 57 (49, 65) | 53 (44, 58) | 55 (47, 63) |  |
 Min–max | 16 – 86 | 17 – 88 | 16 – 88 |  |
Sex | ||||
 Male | 45 (26%) | 25 (35%) | 70 (29%) | 0.173chi2 |
Premorbid mRS | ||||
 N | 170 | 71 | 241 | 0.004tt2 |
 0 | 140 (82%) | 66 (93%) | 206 (85%) |  |
 1 | 17 (10%) | 4 (6%) | 21 (9%) |  |
 2 | 11 (6%) | 1 (1%) | 12 (5%) |  |
 3 | 2 (1%) | 0 (0%) | 2 (1%) |  |
Hunt and Hess score | ||||
 N | 170 | 71 | 241 |  < 0.001tt2 |
 Mean ± SD | 3.4 ± 1.3 | 2 ± 1.1 | 3 ± 1.4 |  |
 Median (Q1, Q3) | 3 (3, 5) | 2 (1, 3) | 3 (2, 4) |  |
 Min–max | 1 – 5 | 1 – 5 | 1 – 5 |  |
 1 | 16 (9%) | 32 (45%) | 48 (20%) |  |
 2 | 22 (13%) | 18 (25%) | 40 (17%) |  |
 3 | 48 (28%) | 12 (17%) | 60 (25%) |  |
 4 | 39 (23%) | 8 (11%) | 47 (20%) |  |
 5 | 45 (26%) | 1 (1%) | 46 (19%) |  |
Aneurysm treatment | ||||
 Coiling | 127 (75%) | 61 (86%) | 188 (78%) | 0.047chi2 |
 Flow diverter | 5 (3%) | 3 (4%) | 8 (3%) |  |
 Web device | 3 (2%) | 3 (4%) | 6 (2%) |  |
 Clipping | 32 (19%) | 3 (4%) | 35 (15%) |  |
 Coiling + Clipping | 3 (2%) | 1 (1%) | 4 (2%) |  |
Duration of stay Neuro-ICU [days] | ||||
 N | 170 | 71 | 241 |  < 0.001tt2 |
 Median (Q1, Q3) | 22 (15, 29) | 7 (2, 14) | 18 (10, 27) |  |
 Min–max | 1 – 65 | 0 – 37 | 0 – 65 |  |
Forced hypertension | ||||
 No | 27 (16%) | 39 (55%) | 66 (27%) |  < 0.001chi2 |
 Yes | 143 (84%) | 32 (45%) | 175 (73%) |  |
Endovascular therapy | ||||
 No | 59 (35%) | 53 (75%) | 112 (46%) |  < 0.001chi2 |
 Yes | 111 (65%) | 18 (25%) | 129 (54%) |  |
Number of ETs per case | ||||
 N | 170 | 71 | 241 |  < 0.001tt2 |
 Mean ± SD | 1.1 ± 1.2 | 0.42 ± 0.89 | 0.93 ± 1.2 |  |
 Min–max | 0 – 7 | 0 – 4 | 0 – 7 |  |
Treatment during ET | ||||
 Nimodipine only | 57 (34%) | 11 (15%) | 68 (28%) |  |
 PTA only | 5 (3%) | 0 (0%) | 5 (2%) |  |
 Nimodipine + PTA | 44 (26%) | 7 (10%) | 51 (21%) |  |
EVD | ||||
 No | 11 (6%) | 40 (56%) | 51 (21%) |  < 0.001chi2 |
 Yes | 159 (94%) | 31 (44%) | 190 (79%) |  |
Delayed cerebral ischemia | ||||
 No | 43 (25%) | 53 (75%) | 96 (40%) |  < 0.001chi2 |
 Yes | 127 (75%) | 18 (25%) | 145 (60%) |  |
mRS at final follow-up | ||||
 N | 154 | 63 | 217 |  < 0.001tt2 |
 Missing | 16 (9%) | 8 (11%) | 24 (10%) |  |
 Median (Q1, Q3) | 4 (2, 6) | 0 (0, 2) | 3 (1, 5) |  |
Duration of follow-up [months] (including in-hospital mortality) | ||||
 N | 153 | 63 | 216 | 0.003tt2 |
 Missing | 17 (10%) | 8 (11%) | 25 (10%) |  |
 Mean ± SD | 19 ± 28 | 34 ± 33 | 24 ± 30 |  |
 Median (Q1, Q3) | 6 (1, 25) | 24 (7, 50) | 9 (2, 34) |  |